1418112-83-0

Basic information

• Product Name: 3-methylazetidine-1-sulfonamide
• Synonyms: 3-methylazetidine-1-sulfonamide
• CAS NO: 1418112-83-0
• Molecular Weight: 150.202
• Mol File: 1418112-83-0.mol

Chemical Properties

• CAS DataBase Reference: 3-methylazetidine-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methylazetidine-1-sulfonamide(1418112-83-0)
• EPA Substance Registry System: 3-methylazetidine-1-sulfonamide(1418112-83-0)

Safety Data

• Hazardous Substances Data: 1418112-83-0(Hazardous Substances Data)

Upstream product

• 1418112-84-1 benzyl 3-methylazetidin-1-ylsulfonylcarbamate 

Downstream Products

• 1418112-80-7 N-(6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzyl-thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide 
• 1418112-77-2 N-(6-{[(2R,3S)-3,4-dihydroxy-2-butanyl]oxy}-2-[(4-fluorobenzyl)sulfanyl]-4-pyrimidinyl)-3-methyl-1-azetidinesulfonamide 

Relevant articles and documents

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.